EMEA-000317-PIP02-18-M01
Key facts
| Invented name |
Rekambys
|
| Active substance |
rilpivirine
|
| Therapeutic area |
Infectious diseases
|
| Decision number |
P/0397/2022
|
| PIP number |
EMEA-000317-PIP02-18-M01
|
| Pharmaceutical form(s) |
Prolonged release suspension for injection
|
| Condition(s) / indication(s) |
Treatment of human immunodeficiency virus (HIV-1) infection
|
| Route(s) of administration |
Intramuscular use
|
| Contact for public enquiries |
Janssen-Cilag International N.V.
Tel. +32 14602111 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|